Skip to main content
Back
Watch Compare

Rein Therapeutics, Inc.

Data quality: 100%
RNTX
NASDAQ Manufacturing Chemicals
$1.78
▲ $0.15 (9.20%)
6 months return
—
Momentum
Neutral
ROE
-105.88%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-105.88%
Below sector avg (-54.47%)
ROIC-81.84%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.90
Interest CoverageN/A

Valuation

PE (TTM)
-0.84
Above sector avg (-1.49)
P/B Ratio0.90
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -19.36 M

Price History

Financial Trends

Analyst Price Target

1 analyst
Buy
+461.8%
upside to target
Current
$1.78
Consensus Target
$10.00
$10.00
Low
$10.00
High
Forecast
Forward EPS
-$1.33
Est. Revenue
0.0

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.49 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.25 -$0.28 -$0.21 -$1.22 — —
Estimate -$0.21 -$0.22 -$0.24 -$0.22 -$0.49 -$0.49
Surprise -19.05% -27.27% +12.50% -467.44% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -105.88% · Net Margin: N/A
Revenue (TTM) 0.0 Net Income (TTM) -49.87 M
ROE -105.88% ROA -89.71%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -19.36 M
ROIC -81.84% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0.90
Debt / Equity N/A Current Ratio 0.90
Interest Coverage N/A Asset Turnover 0.00
Working Capital -570,000 Tangible Book Value -2.34 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.84 · EV/EBITDA: N/A
P/E Ratio -0.84 Forward P/E N/A
P/B Ratio 0.90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -46.34%
Market Cap 41.78 M Enterprise Value 37.73 M

Per Share

EPS: -1.96 · FCF/Share: -0.69
EPS (Diluted TTM) -1.96 Revenue / Share 0.00
FCF / Share -0.69 OCF / Share -0.69
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 38.82% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 38.82%
SBC-Adj. FCF -21.84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -49.87 M -62.88 M -15.73 M -27.33 M -26.16 M
EPS (Diluted) -1.96 -3.51 -3.42 -6.02 —
Gross Profit — — — — —
Operating Income -50.63 M -65.11 M -16.28 M -27.65 M -26.61 M
EBITDA — — — — —
R&D Expenses 11.03 M 14.25 M 3.99 M 17.97 M 17.01 M
SG&A Expenses — — — — —
D&A 1,000.0 63,000.0 119,000.0 169,000.0 121,000.0
Interest Expense — — — — —
Income Tax -712,000.0 -1.54 M 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 24.16 M 62.19 M 106.01 M 22.01 M 48.48 M
Total Liabilities 7.24 M 7.80 M 7.71 M 3.38 M 4.58 M
Shareholders' Equity 16.92 M 54.39 M 6.89 M 18.62 M 43.90 M
Total Debt — — — — —
Cash & Equivalents 3.22 M 12.87 M 17.31 M 5.19 M 3.60 M
Current Assets 4.33 M 13.66 M 18.27 M 21.87 M 48.18 M
Current Liabilities 6.18 M 5.75 M 4.39 M 3.38 M 4.51 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -0.8 -1.5
P/B 0.9 1.6
ROE % -105.9 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3